Valrubicin: Difference between revisions
m (Protected "Valrubicin": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +)) |
||
Line 1: | Line 1: | ||
{{drugbox | IUPAC_name = [2-oxo-2-[2,5,12-trihydroxy-4- [5-hydroxy-6-methyl-4- (2,2,2-trifluoroacetyl) amino-tetrahydropyran-2-yl] oxy-7-methoxy-6,11-dioxo-1,2,3,4-tetrahydrotetracen- 2-yl]-ethyl] pentanoate | image = Valrubicin.svg | CAS_number = 56124-62-0 | ATC_prefix = L01 | ATC_suffix = DB09 | ATC_supplemental = | PubChem = 41744 | DrugBank = APRD00662 | C=34 | H=36 | F=3 | N=1 | O=13 | molecular_weight = 723.644 g/mol | bioavailability = | protein_bound = >99% | metabolism = | elimination_half-life = | pregnancy_category = | legal_status = | routes_of_administration = }} | {{drugbox | IUPAC_name = [2-oxo-2-[2,5,12-trihydroxy-4- [5-hydroxy-6-methyl-4- (2,2,2-trifluoroacetyl) amino-tetrahydropyran-2-yl] oxy-7-methoxy-6,11-dioxo-1,2,3,4-tetrahydrotetracen- 2-yl]-ethyl] pentanoate | image = Valrubicin.svg | CAS_number = 56124-62-0 | ATC_prefix = L01 | ATC_suffix = DB09 | ATC_supplemental = | PubChem = 41744 | DrugBank = APRD00662 | C=34 | H=36 | F=3 | N=1 | O=13 | molecular_weight = 723.644 g/mol | bioavailability = | protein_bound = >99% | metabolism = | elimination_half-life = | pregnancy_category = | legal_status = | routes_of_administration = }} | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
Line 16: | Line 16: | ||
{{Chemotherapeutic agents}} | {{Chemotherapeutic agents}} | ||
[[Category:chemotherapeutic agents]] | [[Category:chemotherapeutic agents]] | ||
[[Category:cancer treatments]] | [[Category:cancer treatments]] |
Revision as of 17:17, 20 August 2012
File:Valrubicin.svg | |
Clinical data | |
---|---|
ATC code | |
Pharmacokinetic data | |
Protein binding | >99% |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C34H36F3NO13 |
Molar mass | 723.644 g/mol |
WikiDoc Resources for Valrubicin |
Articles |
---|
Most recent articles on Valrubicin |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Valrubicin at Clinical Trials.gov Clinical Trials on Valrubicin at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Valrubicin
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Valrubicin Discussion groups on Valrubicin Patient Handouts on Valrubicin Directions to Hospitals Treating Valrubicin Risk calculators and risk factors for Valrubicin
|
Healthcare Provider Resources |
Causes & Risk Factors for Valrubicin |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Overview
Valrubicin (N-trifluoroacetyladriamycin-14-valerate, Valstar®) is a chemotherapy drug used to treat bladder cancer. Valrubicin is a semisynthetic analog of the anthracycline doxorubicin, and is administered by infusion directly into the bladder.
Dosage
800 mg weekly for 6 weeks
Side effects
- Blood in urine
- Incontinence
- painful or difficult urination
- Unusually frequent urination
- Pages with script errors
- Pages with broken file links
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Chemotherapeutic agents
- Cancer treatments
- Quinones